MeVis Medical Solutions (M3V) AI Stock Analysis

MeVis Medical Solutions

(XETRA:M3V)

Select Model

Rating:66Neutral

Price Target:EUR 22.00▲(8.91% Upside)

Action:downgraded

Date:08/05/26

MeVis benefits from a robust balance sheet, zero debt, and healthy cash generation, which support its attractive dividend yield. However, declining revenue and profitability, coupled with bearish technical signals, offset these strengths. The stock's valuation is reasonable, leading to a neutral overall assessment.

Positive Factors

Debt-free balance sheetA debt-free structure gives MeVis greater resilience through operating weakness because no interest burden or refinancing schedule competes for cash. Stable equity also preserves flexibility to fund product development, shareholder returns, or strategic investment without relying on additional borrowing.

Negative Factors

Persistent revenue declineThree consecutive annual revenue declines point to a sustained weakening in demand, market reach, or customer expansion rather than a single-period fluctuation. Continued top-line contraction can reduce operating leverage, limit reinvestment capacity, and make future earnings growth harder to restore.

MeVis Medical Solutions (M3V) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 37.13M
Dividend Yield: 4.66%
Average Volume (3M): 172
Price to Earnings (P/E): 26.8
Beta (1Y): 0.17
Revenue Growth: -6.92%
EPS Growth: -67.82%
Country: Germany
Employees: 127
Sector: General
Sector Strength: 55
Industry: Software - Application

MeVis Medical Solutions Business Overview & Revenue Model

Company Description

MeVis Medical Solutions AG develops software for recording, analyzing, and evaluating image data to manufacturers of medical devices, providers of medical IT platforms, and clinical end customers in the United States and Europe. The company provides...

MeVis Medical Solutions Financial Statement Overview

Summary

MeVis maintains a debt-free balance sheet (score 95) and strong cash flow generation (score 78), providing financial flexibility. However, revenue and net profit have been declining (income statement score 52), indicating top-line pressure. Overall, the company is fundamentally sound but faces growth challenges.

Income Statement

52Neutral

Balance Sheet

95Very Positive

Cash Flow

78Positive

Financial statement breakdown
Breakdown	TTM	Sep 2025	Sep 2024	Sep 2023	Sep 2022	Sep 2021
Income Statement
Total Revenue	15.48M	16.06M	16.97M	17.34M	18.76M	16.21M
Gross Profit	3.13M	15.69M	16.48M	7.00M	18.02M	15.78M
EBITDA	791.01K	3.43M	4.82M	5.17M	7.97M	4.77M
Net Income	1.38M	3.17M	4.56M	4.92M	7.79M	4.55M
Balance Sheet
Total Assets	23.16M	25.89M	26.48M	28.05M	31.20M	27.53M
Cash, Cash Equivalents and Short-Term Investments	3.65M	6.52M	6.53M	7.74M	9.32M	7.62M
Total Debt	0	0	0	0	0	0
Total Liabilities	5.34M	8.06M	8.66M	10.23M	13.38M	9.71M
Stockholders Equity	17.83M	17.83M	17.83M	17.83M	17.83M	17.83M
Cash Flow
Free Cash Flow	0	3.74M	2.84M	5.77M	4.72M	9.08M
Operating Cash Flow	0	3.88M	3.15M	5.85M	4.86M	9.13M
Investing Cash Flow	0	945.46K	906.80K	989.98K	58.66K	111.63K
Financing Cash Flow	0	-4.56M	-4.92M	-7.79M	-4.55M	-5.70M

MeVis Medical Solutions Technical Analysis

Technical Analysis SentimentNegative

Last Price20.20

Price Trends

50DMA22.66Negative

100DMA23.25Negative

200DMA23.43Negative

Market Momentum

MACD-0.67Positive

RSI24.85Positive

STOCH15.79Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:M3V, the sentiment is Negative. The current price of 20.20 is below the 20-day moving average (MA) of 21.44, below the 50-day MA of 22.66, and below the 200-day MA of 23.43, indicating a bearish trend. The MACD of -0.67 indicates Positive momentum. The RSI at 24.85 is Positive, neither overbought nor oversold. The STOCH value of 15.79 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DE:M3V.

MeVis Medical Solutions Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

DE:M3V against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DE:SHL	70Outperform	EUR 47.86B	21.66	12.00%	2.33%	-0.92%	2.06%
DE:EUZ	69Neutral	EUR 832.23M	16.63	19.49%	1.65%	4.42%	35.68%
DE:DRW8	67Neutral	EUR 1.64B	11.28	10.20%	2.93%	5.06%	40.18%
DE:M3V	66Neutral	EUR 37.13M	26.84	7.77%	4.66%	-6.92%	-67.82%
DE:SBS	57Neutral	EUR 273.51M	-562.50	-0.17%	2.67%	―	―
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
DE:COP	53Neutral	EUR 1.50B	43.42	4.19%	1.74%	―	―

* General Sector Average

Performance Comparison

DE:M3V and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:M3V	MeVis Medical Solutions	20.40	-3.89	-16.00%
DE:COP	CompuGroup Medical	28.45	4.29	17.74%
DE:DRW8	Draegerwerk AG & Co. KGaA (0MT8)	75.40	17.43	30.06%
DE:EUZ	Eckert & Ziegler Strahlen und Medizintechnik	13.30	-2.88	-17.79%
DE:SBS	STRATEC Biomedical	22.50	0.99	4.62%
DE:SHL	Siemens Healthineers	42.89	-5.20	-10.82%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 04, 2026

MeVis Medical Solutions AI Stock Analysis